At the IGTP TODAY

News

- Campus Can Ruti, Research

A team at Germans Trias treat a patient with a new bio-implant to repair heart tissue after a heart attack

The pioneering surgery that took place last May at the Germans Trias Hospital. The bio-implant, based on umbilical cord stem cells, has been developed by the Cardiovascular Disease Research Group (ICREC) at Germans Trias, led by Antoni Bayés-Genís in a research line, which they have been pursuing for 10 years. The new therapy has been developed with the collaboration of the Blood and Tissue Bank (BST) and the Institute of Bioengineering of Catalonia (IBEC); this is the first step of the application in clinical practice and the group will continue to monitor safety and the capacity of cardiac tissue to recover

- Research

Science at the IGTP becomes performance art in the hands of the Fura dels Baus’s Epicalab

Two groups at the IGTP have taken part in the workshop "Complex Systems" organized by the Èpica Foundation. The experience is a first for the IGTP and has meant that art and science have worked together to produce results for both of them. Èpica is a space for interdisciplinary learning and training for the performing arts run by the Fura dels Baus. The results of the workshop are based on research projects from the IGTP and will be shown this Friday and Saturday 29 and 30 November at the Èpica headquarters in Badalona.

- Research

A study of an atypical form of DM1 will improve the diagnosis and management of this rare disease

The Neuromuscular and Neuropediatric Group at the IGTP, led by Gisela Nogales-Gadea have identified a subset of patients with an atypical type of myotonic dystrophy type 1 (MD1), which develops later and with more severe symptoms than usual. This has important implications for diagnosis of these patients, who can be misdiagnosed or not given the correct prognosis. It is also vital for managing the disease correctly in patients and their families. The study has been published in Human Mutation.

Germans Trias Professionals organize the first National Meeting on Neurofibromatosis Type 2

Last Friday the first update meeting at national level to take a global view of the healthcare situation and present the latest research data for Neurofibromatosis type 2 (NF2) took place at the IGTP. This pioneering event was organized by the members of the National Reference Centre in genetic neuro-cutaneous syndromes (Facomatosis), (CSUR) on the Can Ruti Campus and also included patients and families affected by the disease.

- Research

Talking about diabetes type 1 for World Diabetes Day

To celebrate World Diabetes Day we will literally be talking about the illness at the IGTP; several members of the Immunology of Diabetes Group, which is led by Marta Vives-Pi and concentrates on research into diabetes type 1, will be taking part in talks and discussions in scientific and public forums during the next few days.

- Research

A new step towards reaching the WHO targets to eliminate HCV infection

Researchers from the Germans Trias i Pujol Hospital and Institute have developed and successfully validated a new one-step screening method to diagnose active hepatitis C virus (HCV) infection in people who inject drugs, a main high risk group. The new method validated will permit better planning of future more effective actions to improve diagnostics and treatments for this vulnerable group. The study also estimated the prevalence of HCV infection in this community and showed that many people tested do not know that they are infected.

- Research

The Hereditary Cancer group expands the use of its gene panel to test for more RASopathies

In 2017 the team designed and tested a gene panel, in collaboration with the ICO, to standardize and simplify genetic testing for hereditary cancer. In the current work the group has validated and extended the use of this panel in the routine genetic testing for  different RASopathies. These are other genetic diseases caused by mutations in genes of the Ras/MAPK pathway for which patients exhibit an overlapping clinical presentation with NF1, especially in children.